Oncology

Session # Abstract ID: 581999

Discrepancies Between Payer Coverage and Consensus Guidelines for Personalizing Hereditary Cancer Risk 

  • Comparison of HBOC genetic testing policies from three US insurers to NCCN v2.2019 medical management guidelines available for 16 genes identified that among insurers A, B, and C, 6(37.5%), 8(50.0%) and 15(93.8%) of the genes were covered, respectively.
  • On a patient level, limiting genetic testing to payer coverage resulted in unidentified mutations and missed opportunities to personalize cancer risk management in accordance with expert consensus.
  • This data supports the expansion of insurer genetic testing policies to include MGPT for patients at high-risk of HBOC.

  • Authors: Jill Dolinsky; Lily Hoang; Patrick Reineke; Nancy Niguidula; Victoria Ellis; Emily Dalton; Jessica Profato; Greg Nogle; Holly LaDuca
  • Conference: American Society of Breast Surgeons (ASBrS) 2019
  • Date: Friday, May 03, 2019 6:00pm - 7:30pm

Search Results

Start your search...